QurieGen – Strategic Technological Analysis
27 pages · PDF · 16 September 2025 · Licensed single-user copy, watermarked to the buyer
Tactical Biotechnology, Human Enhancement & MedTech Netherlands
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
QurieGen is a young European biotech venture pushing the frontiers of rapid genomic analysis to accelerate drug development. Founded in 2022 as a spin-off from Radboud University in the Netherlands, this company has quickly gained attention for its innovative “single-cell” platform that decodes how individual cells respond to drugs .
By combining microfluidics, genomics, and data science, QurieGen aims to map complex cellular behaviors in ways that traditional lab tests cannot, offering a kind of “Google Maps for cells” to guide precision medicine .
Key questions this report answers
- How does QurieGen's single-cell platform combine microfluidics, genomics and data science to decode drug responses?
- What is the maturity of this Radboud University spin-off's (2022) rapid genomic-analysis technology?
- Which precision-medicine and drug-development markets and partners does QurieGen serve?
- What capability gaps or dependencies affect scaling its 'Google Maps for cells' platform?
Who it's for
Investors screening QurieGen, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (16 September 2025). You receive a 27-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Biotechnology, Human Enhancement & MedTech · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →